Perspective's Fast Track and Keytruda deal show how radiopharma builds value before M&A

What happened

Perspective Therapeutics (CATX), an alpha-emitting radiopharmaceutical developer, announced on 9 November that the FDA has granted Fast Track designation to PSV359. The company also signed a deal involving Merck's Keytruda. It reported EU orphan status for bamzireotide navoxetan, about $202 million in cash and a third-quarter net loss of $32.4 million.

The material available does not give the terms of the Merck arrangement: structure, economics, and whether it covers clinical supply, co-development or something else. Until those details emerge, the deal's significance rests on who the counterparty is rather than on what it pays. A relationship with the owner of the leading PD-1 franchise is a credibility signal for a clinical-stage company, but it is not a commercial transaction in the sense of an upfront payment or an equity stake.

The strategic logic

The announcement bundles three kinds of regulatory and partnering validation. Fast Track is a process benefit, enabling more frequent FDA interaction and, where criteria are met, rolling review. It does not predict efficacy. EU orphan status for bamzireotide navoxetan adds a regional regulatory incentive. The Keytruda deal links the pipeline to the standard-of-care backbone in many solid-tumour settings, which is where combination data would eventually be judged.

The balance sheet frames the timeline. Cash of about $202 million against a $32.4 million quarterly net loss implies roughly six quarters at the Q3 pace on simple division. Net loss is not cash burn, and the material includes no runway guidance, so this is a rough yardstick rather than a forecast. Still, it indicates that Perspective's next financing or partnering decision is likely to be shaped by what it can show clinically in that window. Regulatory designations and a big-pharma relationship are the kind of milestones that tend to support that conversation.

Competitive and deal context

The rest of the week's deal flow shows buyers pursuing different routes to growth. CorMedix (CRMD) agreed to buy substantially all of Heron Therapeutics' (HRTX) assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, for about $222.6 million upfront plus shares and contingent earn-outs, with closing expected in Q1 2027. It is a commercial-portfolio consolidation in hospital products for postoperative pain and nausea and vomiting. Perspective is the opposite end of the spectrum, with no approved product in the material and value tied to development milestones.

Capacity and services are also being consolidated. Charles River (CRL) will acquire Frontage's Exton bioanalysis and DMPK businesses for about $470 million, with up to $75 million in performance-based payments, through a consortium structure that first takes Frontage private. Radiopharma developers like Perspective depend on specialised development infrastructure, so CRO investment in this kind of work is relevant background, though the material does not link the two.

Smaller and regional deals round out the picture. Edesa Biotech (EDSA) licensed paridiprubart to Kyorin for Japan, with $12 million upfront and a headline value above $140 million, a reminder that the upfront is often a small share of announced totals. Acrivon (ACRV) bought a Phase 2-ready oral JAK1 inhibitor, ACR-525, and a preclinical PKCθ programme from Aqilion for undisclosed cash, with no royalties or milestones owed, an unusually clean structure that moves an oncology biotech into immunology. ANI Pharmaceuticals (ANIP) proposed an offer for Egetis Therapeutics to add EMCITATE to its rare disease portfolio, and that deal has not closed. Armada Acquisition Corp. III (AACI) agreed to merge with cannabinoid API maker Brains Bioceutical at an implied pre-money equity value of about $750 million, showing that SPAC routes are still being used.

Risks

For Perspective, the main risks are the ones Fast Track cannot remove: clinical outcomes, and the funding needed to reach them. The undisclosed Merck terms leave open how much of the benefit is strategic and how much financial. Designations can also be overread; they speed interaction with regulators but do not alter approval standards.

For the broader deal set, execution risk is concentrated in the pending transactions. CorMedix's Heron deal has a Q1 2027 closing target and contingent earn-outs. ANI's Egetis approach is only a proposal. Charles River's structure depends on the Frontage take-private happening first. Armada's merger remains subject to closing conditions.

What to watch

First, whether Perspective discloses the Merck deal's scope and any clinical plans for PSV359 under Fast Track. Second, how the company manages cash against its roughly $32 million quarterly loss, including any financing or partnering. Third, whether the EU orphan designation for bamzireotide navoxetan feeds into regional strategy. More broadly, watch whether the closing of the Heron, Frontage and Egetis transactions confirms that buyers are prepared to pay for assets with revenues or capacity rather than early-stage science alone.